Other genetic alterations identified in FGFR-inhibitor-resistant GC clones include a JHDM1D–BRAF fusion, which was observed in a pre-clinical model of acquired resistance [107], while a recent clinical study reported the emergence of an FGFR2–ACSL5 fusion upon progression in a patient with FGFR2-amplified GC treated with the FGFR inhibitor LY2874455 [108]. This evidence concerns the gene BRAF and gastric cancer.